Viewing nowLyrica Orally Disintegrating Tablet 50mg (Pregabalin)
Pregabalin 50mg
Orally disintegrating Tablet · Prescription medication
GL Pharma Co., Ltd.

MFDS item code 202600403 · Approved 2026.02.12
Treatment of neuropathic pain, adjunctive treatment of partial-onset epileptic seizures, and treatment of fibromyalgia
This medication is used for the treatment of peripheral and central neuropathic pain in adults. Additionally, it is used as an adjunctive treatment for partial seizures in epilepsy patients with or without secondary generalization. It is also effective in alleviating symptoms in patients with fibromyalgia. This medication helps with a variety of neurological disorders and pain relief.
This drug is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Place it on the tongue and, once it has disintegrated, swallow it without water. This drug is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be done gradually over a period of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Because the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This drug is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Use is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior, so any changes in mood or unusual behavior should be reported to a healthcare professional immediately during the course of treatment. Patients with a history of allergy or hypersensitivity to any component of this medication should not use it. Diabetic patients may require adjustment of their blood sugar control medications due to weight gain. If serious allergic reactions such as angioedema occur, the medication should be stopped immediately and medical advice sought. Elderly patients should be cautious of the risk of falls due to dizziness or drowsiness, especially during the initial stages of use. Patients may experience temporary blurred vision or changes in vision; if symptoms persist, consult a healthcare professional. Sudden discontinuation of this medication can lead to withdrawal symptoms including insomnia, headache, anxiety, and others, so it should be tapered gradually in consultation with a healthcare professional. Patients with a history of drug abuse are at risk of misuse or dependency on this medication and should exercise caution. Patients with reduced kidney function may require dose adjustments of this medication. Patients with heart disease should be cautious of the risk of congestive heart failure while taking this medication. Taking this medication with opioid analgesics can enhance central nervous system depressant effects, increasing the risk of respiratory depression; caution is advised. This medication can cause dizziness and drowsiness, so caution is necessary when driving or operating dangerous machinery. In early pregnancy, there is a risk of congenital anomalies to the fetus; therefore, pregnant women are advised not to take this medication, and women of childbearing potential should use effective contraception. While breastfeeding, this medication may pass into breast milk and affect an infant, so consideration should be given to stopping breastfeeding or the medication. In the case of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur, and immediate medical treatment should be sought. Keep out of reach of children, and do not transfer to another container to maintain the quality of the medication. During treatment with this medication, serious adverse reactions such as skin rash, fever, and breathing difficulties may occur; if these symptoms arise, the medication should be stopped immediately and medical advice sought.
Suicidal thoughts, suicidal behavior, depression, abnormal mood and behavioral changes, angioedema, facial swelling, periorbital edema, upper respiratory edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like symptoms, restlessness, depression, suicidal thoughts, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinopharyngitis, neutropenia, increased appetite, anorexia, hypoglycemia, confusion, disorientation, irritability, euphoria, reduced libido, depersonalization, paraphilia, agitation, mood swings, emotional lability, emotional uplift, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, abnormal motor coordination, balance disorders, amnesia, attention deficits, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, type 1 muscle cramps, reflex reduction, abnormal movements, psychomotor agitation, positionally induced dizziness, hypersensitivity, burning sensation, activity tremors, syncope, confusion, hypokinesia, olfactory disturbances, loss of taste, writing impairment, diplopia, dry eyes, conjunctival edema, decreased vision, ocular pain, eye strain, increased tear secretion, ocular irritation, mydriasis, perceptual depth changes during vibration, strabismus, brightness changes in vision, vertigo, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, vomiting, abdominal distension, constipation, dry mouth, abdominal bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rashes, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, reduced urine output, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, edema, gait disturbances, falls, feelings of intoxication, sensory disturbances, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorders, drowsiness, confusion state, agitation, restlessness, worsening of seizures, gastrointestinal disturbances, tinnitus, sleep disorders, skin disorders, increased BUN, bloody stools
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage will help to preserve the effectiveness of the medication for a longer period.
Yellow round orally disintegrating tablet
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Orally disintegrating Tablet · Prescription medication
GL Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.